Deal targets European market for CNS candidate

UK-based ADVANZ PHARMA has acquired exclusive rights to register and commercialize AT-007, a Phase III development compound for the treatment of several rare neurological diseases, including galactosemia and SORD deficiency, in the European Economic Area, the UK, and Switzerland.

This follows the speciality and hospital pharmaceuticals company’s announcement of a deal with US biopharma Applied Therapeutics (Nasdaq: APLT), financial terms of which have not been disclosed.

Applied will be responsible for the clinical development and supply of AT-007, a CNS penetrant aldose reductase inhibitor. The London-based company, meanwhile, will manage the registration and commercialization in the region covered by the agreement, leveraging its existing specialty, hospital, and rare disease expertise and infrastructure to ensure patient access.